Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
104.40    1.20 (1.16%)
Bid:
104.40
Ask:
105.20
Spread: 0.80 (0.766%)
Market Cap: £171.16m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

12 May 2011 07:00

RNS Number : 4433G
Yule Catto & Co PLC
12 May 2011
 



12 May 2011

 

Yule Catto & Co plc (the "Group") 

 

Interim Management Statement

 

At this afternoon's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter Wood will make the following statement which also comprises the Group's interim management statement for the period 1 January 2011 to date.

 

The Group's earnings for the first quarter were well ahead of the same period last year excluding any impact of the PolymerLatex acquisition, and the Board's expectations for financial performance for 2011 remain unchanged.

 

Overall demand in Yule Catto's Polymer business was solid. Asian demand was strong through the quarter, whilst Europe firmed after a slow start in the UK. Ongoing very substantial monomer price increases have had to be passed on to customers, resulting in the usual temporary margin compression as the increases are recovered and target unit margins per tonne restored. Consequently, although volumes increased in Polymers and turnover was strongly ahead, operating profit was flat year on year in the first quarter. Whilst Europe lagged the prior year, Asia was ahead, despite, as expected, profits being temporarily constrained by capacity during the quarter. This position will be resolved in the course of the second quarter with the new 15,000 tonne nitrile expansion coming on line and some spare capacity in the acquired PolymerLatex nitrile assets. In April, the existing Yule Catto polymer business performed ahead of prior year.

 

The acquisition of PolymerLatex completed at the end of March as anticipated. Integration planning progressed through the first quarter and is now being implemented. Post acquisition, the synergy potential has been confirmed, and management remain highly confident that at least £20m of synergies will be delivered as disclosed at the time of the acquisition announcement and to the same timetable. Regular updates on progress in delivering these synergies will be provided to investors, with the first update to be delivered with the group's half year results in August. As at the date of this statement, actions taken to date have already delivered synergies with an annual run rate value of approximately £2m.

 

PolymerLatex itself traded comfortably ahead of last year in the first quarter, and this has continued through April. The business benefited from good demand in central Europe for latex and volume growth in its Malaysian nitrile facility. Plans are already being developed for very substantial increases in capacity in Asia for nitrile and SBR latex to be brought on line before the end of 2012.

 

In the Group's other businesses in the first quarter, the Pharma division performed well ahead of what was a very weak result in the same period last year, whilst William Blythe continued to grow profits strongly.

 

Net debt at the end of the quarter stood at £235m reflecting the impact of the acquisition of PolymerLatex, in line with the Group's forecasts at the time of the acquisition announcement.

 

- Ends -

 

ENQUIRIES:

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

David Blackwood, Group Finance Director

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

John Olsen

Ian Payne

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLFFLFERILLIL
Date   Source Headline
29th Sep 20227:00 amRNSTrading update
23rd Sep 20229:23 amRNSHolding(s) in Company
12th Sep 20223:27 pmRNSHolding(s) in Company
6th Sep 20228:15 amRNSHolding(s) in Company
12th Aug 20229:22 amRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSDirector/PDMR Shareholding
9th Aug 20224:09 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSDirector/PDMR Shareholding
5th Aug 20221:20 pmRNSHolding(s) in Company
5th Aug 202211:27 amRNSDirector/PDMR Shareholding
4th Aug 20222:57 pmRNSDirector/PDMR Shareholding
4th Aug 20222:35 pmRNSDirector/PDMR Shareholding
3rd Aug 202212:29 pmRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSResults for the six months ended 30 June 2022
15th Jul 20222:32 pmRNSHolding(s) in Company
8th Jul 202210:23 amRNSHolding(s) in Company
1st Jul 20227:00 amRNSChief Financial Officer
30th Jun 20225:04 pmRNSHolding(s) in Company
21st Jun 20227:00 amRNSAppointment of Non-Executive Director
17th May 202212:55 pmRNSHolding(s) in Company
5th May 202212:39 pmRNSHolding(s) in Company
4th May 20224:46 pmRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSAppointment of Joint Corporate Brokers
28th Apr 202212:24 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 2022 trading update
26th Apr 20229:33 amRNSHolding(s) in Company
20th Apr 20224:13 pmRNSHolding(s) in Company
5th Apr 20224:18 pmRNSDirector/PDMR Shareholding
1st Apr 20221:34 pmRNSCompletion of adhesives acquisition
29th Mar 20223:17 pmRNSHolding(s) in Company
29th Mar 20223:14 pmRNSDirector/PDMR Shareholding
25th Mar 20222:03 pmRNSAnnual Financial Report
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:48 pmRNSDirector/PDMR Shareholding
14th Mar 20229:35 amRNSHolding(s) in Company
9th Mar 202212:52 pmRNSDirector/PDMR Shareholding
8th Mar 20223:22 pmRNSDirector/PDMR Shareholding
8th Mar 20223:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20227:00 amRNSPreliminary Results for the year ended 31 Dec 2021
14th Feb 20227:00 amRNSPre-close trading update
10th Feb 20223:10 pmRNSNOTIFICATION OF MAJOR HOLDINGS
22nd Dec 20215:10 pmRNSDirector/PDMR Shareholding
21st Dec 20213:09 pmRNSDirector/PDMR Shareholding
20th Dec 20213:40 pmRNSDirector/PDMR Shareholding
17th Dec 202112:29 pmRNSResults of General Meeting
15th Dec 20212:54 pmRNSDirector/PDMR Shareholding
30th Nov 20214:57 pmRNSPUBLICATION OF CIRCULAR
26th Nov 20217:00 amRNSAppointment of Chief Financial Officer
22nd Nov 202110:36 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.